dermatology
Autoimmune diseases

Rituximab needed for its steroid sparing effect in immunobullous disease


There is still a clinical need for corticosteroid-sparing treatments for immunobullous disease in Australia and the availability of rituximab as a first-line treatment would do much to fill the gap. The monoclonal antibody directed against CD20-expressing B-lymphocytes was FDA listed for this indication in 2018 and by the European Medicine Agency (EMA) in March this ...

Already a member?

Enter your email to keep reading.


OR